Pyridazinones as PARP7 Inhibitors (2019)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/664,544, filed Apr 30, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,550,105 | Pyridazinones as PARP7 Inhibitors In force · High confidence UsedRemaining | Ribon Therapeutics Inc. | In force | High confidence | ||
| US 10,870,641 | Pyridazinones as PARP7 Inhibitors In force · High confidence | Ribon Therapeutics, Inc. | In force | High confidence | ||
| US 11,014,913 | Pyridazinones as PARP7 Inhibitors In force · High confidence | Ribon Therapeutics, Inc. | In force | High confidence | ||
| US 11,566,020 | Pyridazinones as PARP7 Inhibitors In force · High confidence | Ribon Therapeutics, Inc. | In force | High confidence | ||
| Application 17/974,830 | Pyridazinones as PARP7 Inhibitors Abandoned Abandoned May 20, 2024 | Ribon Therapeutics, Inc. | Abandoned | Abandoned May 20, 2024 | ||
| Application 18/613,601 | Pyridazinones as PARP7 Inhibitors Pending Not granted | Nerviano Medical Sciences, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Ribon Therapeutics, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.